From the Journals

Noninvasive liver test may help select asymptomatic candidates for heart failure tests

View on the News

Earlier ID of NAFLD, HFpEF?

The 2021 NAFLD clinical care pathway is a shining example of how a simple score like the fibrosis-4 (FIB-4) index – paired sequentially with a second noninvasive test like vibration-controlled elastography – can provide an accurate, cost-effective screening tool and risk stratification and further limit invasive testing such as liver biopsy.

Anand S. Shah, MD, Director of Hepatology, Atlanta VA Healthcare, and Assistant Professor, Emory University Stephanie Heath/Smiling Eyes Inc.

Dr. Anand S. Shah

This study by a cardiovascular group provided a related argument to investigate a tool used for liver fibrosis, FIB-4, as a screen for the difficult-to-diagnosis heart failure with preserved ejection fraction (HFpEF). The current consensus diagnostic algorithm for HFpEF requires an echocardiogram and B-type natriuretic peptide measurement before invasive hemodynamic exercise stress testing. Okamoto et al. showed that a high FIB-4 index correlated to a high-risk HFA-PEFF score and higher all-cause mortality, cardiovascular mortality, and hospital admission for heart failure. Also, a FIB-4 index at the same cutoffs for NASH had high sensitivity and specificity. Further research would be needed to validate the benefit of FIB-4 as a screening test for HFpEF as well as its role in a sequential testing algorithm; additional research also should explore the influence of hepatic damage and fibrosis on cardiac function and morphology.

Broader use of FIB-4 by cardiovascular and hepatology providers may increase earlier identification of NAFLD or HFpEF or both.

Anand S. Shah, MD, is director of hepatology at Atlanta VA Healthcare and assistant professor of medicine, division of digestive disease, department of medicine, Emory University, Atlanta. He has no financial conflicts.


 

FROM GASTRO HEP ADVANCES

A noninvasive test for liver disease may be a useful, low-cost screening tool to select asymptomatic candidates for a detailed examination of heart failure with preserved ejection fraction (HFpEF), say authors of a report published in Gastro Hep Advances.

The fibrosis-4 (FIB-4) index was a significant predictor of high HFpEF risk, wrote Chisato Okamoto, MD, of the department of medical biochemistry at Osaka University Graduate School of Medicine and the National Cerebral and Cardiovascular Center in Japan, and colleagues.

“Recognition of heart failure with preserved ejection fraction at an early stage in mass screening is desirable, but difficult to achieve,” the authors wrote. “The FIB-4 index is calculated using only four parameters that are routinely evaluated in general health check-up programs.”

HFpEF is an emerging disease in recent years with a poor prognosis, they wrote. Early diagnosis can be challenging for several reasons, particularly because HFpEF patients are often asymptomatic until late in the disease process and have normal left ventricular filling pressures at rest. By using a tool to select probable cases from subclinical participants in a health check-up program, clinicians can refer patients for a diastolic stress test, which is considered the gold standard for diagnosing HFpEF.

Previous studies have found that the FIB-4 index, a noninvasive tool to estimate liver stiffness and fibrosis, is associated with a higher risk of major adverse cardiovascular events (MACE) in patients with HFpEF. In addition, patients with nonalcoholic fatty liver disease (NAFLD) have a twofold higher prevalence of HFpEF than the general population.

Dr. Okamoto and colleagues examined the association between the FIB-4 index and HFpEF risk based on the Heart Failure Association’s diagnostic algorithm for HFpEF in patients with breathlessness (HFA-PEFF). The researchers looked at the prognostic impact of the FIB-4 index in 710 patients who participated in a health check-up program in the rural community of Arita-cho, Japan, between 2006 and 2007. They excluded participants with a history of cardiovascular disease or reduced left ventricular systolic function (LVEF < 50%). Researchers calculated the FIB-4 index and HFA-PEFF score for all participants.

First, using the HFA-PEFF scores, the researchers sorted participants into five groups by HFpEF risk: 215 (30%) with zero points, 100 (14%) with 1 point, 171 (24%) with 2 points, 163 (23%) with 3 points, and 61 (9%) with 4-6 points. Participants in the high-risk group (scores 4-6) were older, mostly men, and had higher blood pressure, alcohol intake, hypertension, dyslipidemia, and liver disease. The higher the HFpEF risk group, the higher the rates of all-cause mortality, hospitalization for heart failure, and MACE.

Overall, the FIB-4 index was correlated with the HFpEF risk groups and showed a stepwise increase across the groups, with .94 for the low-risk group, 1.45 for the intermediate-risk group, and 1.99 for the high-risk group, the authors wrote. The FIB-4 index also correlated with markers associated with components of the HFA-PEFF scoring system.

Using multivariate logistic regression analysis, the FIB-4 index was associated with a high HFpEF risk, and an increase in FIB-4 was associated with increased odds of high HFpEF risk. The association remained significant across four separate models that accounted for risk factors associated with lifestyle-related diseases, blood parameters associated with liver disease, and chronic conditions such as hypertension, dyslipidemia, diabetes mellitus, and liver disease.

In additional area under the curve (AUC) analyses, the FIB-4 index was a significant predictor of high HFpEF risk. At cutoff values typically used for advanced liver fibrosis in NAFLD, a FIB-4 cutoff of 1.3 or less had a sensitivity of 85.2%, while a FIB-4 cutoff of 2.67 or higher had a specificity of 94.8%. At alternate cutoff values typically used for patients with HIV/hepatitis C virus infection, a FIB-4 cutoff of less than 1.45 had a sensitivity of 75.4%, while a FIB-4 cutoff of greater than 3.25 had a specificity of 98%.

Using cutoffs of 1.3 and 2.67, a higher FIB-4 was associated with higher rates of clinical events and MACE, as well as a higher HFpEF risk. Using the alternate cutoffs of 1.45 and 3.25, prognostic stratification of clinical events and MACE was also possible.

When all variables were included in the multivariate model, the FIB-4 index remained a significant prognostic predictor. The FIB-4 index stratified clinical prognosis was also an independent predictor of all-cause mortality and hospitalization for heart failure.

Although additional studies are needed to reveal the interaction between liver and heart function, the study authors wrote, the findings provide valuable insights that can help discover the cardiohepatic interaction to reduce the development of HFpEF.

“Since it can be easily, quickly, and inexpensively measured, routine or repeated measurements of the FIB-4 index could help in selecting preferred candidates for detailed examination of HFpEF risk, which may improve clinical outcomes by diagnosing HFpEF at an early stage,” they wrote.

The study was supported by grants from the Osaka Medical Research Foundation for Intractable Disease, the Japan Arteriosclerosis Prevention Fund, the Japan Society for the Promotion of Science, and the Japan Heart Foundation. The authors disclosed no conflicts.

Recommended Reading

Damar Hamlin’s cardiac arrest: Key lessons
MDedge Family Medicine
Geriatrician advises on use of vitamin D supplementation, lecanemab, and texting for her patients
MDedge Family Medicine
AHA scientific statement on rapid evaluation for suspected TIA
MDedge Family Medicine
The longevity gene: Healthy mutant reverses heart aging
MDedge Family Medicine
Medicare policy tweak on LVADs may reduce access to transplant
MDedge Family Medicine
High HDL-C levels linked to increased fracture risk
MDedge Family Medicine
Is preeclampsia a cardiovascular time bomb for mothers?
MDedge Family Medicine
More type 2 diabetes deaths from cancer than heart disease
MDedge Family Medicine
Novel resuscitation for patients with nonshockable rhythms in cardiac arrest
MDedge Family Medicine
Does regular walking improve lipid levels in adults?
MDedge Family Medicine